Table 5.
Current phase I/II, II and III clinical trials using PARP inhibitors for the treatment of pancreatic cancer.
| Drug | Combination | Phase | Primary Outcome | Status | ID |
|---|---|---|---|---|---|
| Niraparib | - | II | ORR (8 weeks) | Recruiting | NCT03553004 |
| Niraparib | - | II | PFS (6 months) | Recruiting | NCT03601923 |
| Niraparib | Dostarlimab | II | DCR (12 weeks) | Recruiting | NCT04493060 |
| Niraparib | Dostarlimab, radiotherapy | II | DCR (2 years) | Recruiting | NCT04409002 |
| Niraparib | Nivolumab or Ipilimumab | I/II | PFS (6 months) | Recruiting | NCT03404960 |
| Rucaparib | Liposomal irinotecan, fluorouracil, leucovorin | I/II | DLT, ORR (3 years), BRR (32 weeks) | Recruiting | NCT03337087 |
| Rucaparib | - | II | AE | Not recruiting | NCT03140670 |
| Rucaparib | - | II | ORR (2 years) | Recruiting | NCT04171700 |
| Veliparib | Gemcitabine hydrochloride + cisplatin | II | Dosing, ORR (5 years) | Not recruiting | NCT01585805 |
| Veliparib | mFOLFIRI | II | OS (3 years) | Not recruiting | NCT02890355 |
| Veliparib | mFOLFOX-6 | I/II | DLT | Not recruiting | NCT01489865 |
| Olaparib | - | II | ORR (24 weeks) | Not recruiting | NCT02677038 |
| Olaparib | - | III | PFS (4 years) | Not recruiting | NCT02184195 |
| Olaparib | Pembrolizumab | II | PFS (3 years) | Recruiting | NCT04548752 |
| Olaparib | Cediranib | II | ORR (4 weeks) | Recruiting | NCT02498613 |
| Olaparib | AZD6738 (Ceralasertib) | II | ORR (2.5 years) | Recruiting | NCT03682289 |
| Fluzoparib | - | III | PFS (3 years) | Recruiting | NCT04300114 |
| Fluzoparib | mFOLFIRINOX | I/II | DLT, MTD, ORR (24 months) | Recruiting | NCT04228601 |
ORR, objective response rate; PFS, progression free survival; DCR, disease control rate; DLT, dose limiting toxicity; BRR, best response rate; AE, adverse events; OS, overall survival; MTD, maximum tolerated dose.